GSK plc
GSK
View Detailed Chart
48.810USD
-0.080-0.16%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
98.25BMarket Cap
13.77P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.16%
5 Days
+0.83%
1 Month
+3.45%
6 Months
+19.46%
Year to Date
+44.32%
1 Year
+43.77%
View Detailed Chart
TradingKey Stock Score of GSK plc
Currency: USD Updated: 2025-12-12Key Insights
GSK plc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 49/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.53.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GSK plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
46.531
Target Price
-4.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
GSK plc Highlights
StrengthsRisks
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Fairly Valued
The company’s latest PE is 13.77, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 388.63M shares, decreasing 2.92% quarter-over-quarter.
Held by Richard Pzena
Star Investor Richard Pzena holds 8.72K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GSK plc Info
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Ticker SymbolGSK
CompanyGSK plc
CEOWaterhouse (Deborah)
Websitehttps://www.gsk.com/
FAQs
What is the current price of GSK plc (GSK)?
The current price of GSK plc (GSK) is 48.810.
What is the symbol of GSK plc?
The ticker symbol of GSK plc is GSK.
What is the 52-week high of GSK plc?
The 52-week high of GSK plc is 49.310.
What is the 52-week low of GSK plc?
The 52-week low of GSK plc is 31.715.
What is the market capitalization of GSK plc?
The market capitalization of GSK plc is 98.25B.
What is the net income of GSK plc?
The net income of GSK plc is 3.29B.
Is GSK plc (GSK) currently rated as Buy, Hold, or Sell?
According to analysts, GSK plc (GSK) has an overall rating of Buy, with a price target of 46.531.
What is the Earnings Per Share (EPS TTM) of GSK plc (GSK)?
The Earnings Per Share (EPS TTM) of GSK plc (GSK) is 3.544.
Related Instruments
+1.83%
+0.76%
-0.31%
-0.51%
+0.15%
+1.33%
+0.11%
-0.23%
-2.28%
+0.23%
-0.37%
+1.37%
+2.40%
-0.23%
-0.73%
-0.74%
0.00%
-1.30%
-3.65%Popular Symbols
